|Own your ow legal marijuana business||
Your guide to making money in the multi-billion dollar marijuana industry
|American Society for Action on Pain|
UI - 000102
AU - Hanks GW
TI - The clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain. [Review]
AB - The mixed agonist-antagonist analgesics do not have a major role in the treatment of chronic pain.
Pentazocine, the first and most widely used of this group of drugs has two major limitations: by mouth it is
not a strong analgesic, but is closer in efficacy to the peripherally acting drugs aspirin and paracetamol than
the weak opioids; and its use is associated with psychotomimetic side effects in 10-20 percent of patients.
The weak opioid analgesics codeine and dextropropoxyphene are more effective and better tolerated than
pentazocine. Buprenorphine is the most useful of the agonist-antagonists in chronic pain patients. It is
potent, long-acting (6-9 h) and effective when given sublingually. However, it has a limited effective dose
range and produces the same side effects as morphine-like drugs, possibly more frequently at equianalgesic
doses. It may be used in the treatment of cancer pain, or in patients with chronic arthritides or other forms of
chronic non-cancer pain who require a potent conventional analgesic, as an alternative to the weak opioids
or to morphine in low doses. Nalbuphine and butorphanol are only available for parenteral administration
which means that their usefulness in the treatment of chronic pain is limited. Meptazinol is restricted by its
manufacturers to 'short term' treatment and there is little information on its use in chronic pain patients.
SO - Drug & Alcohol Dependence 1987;20:339-346